Covid-19 Impact on Induced Pluripotent Stem Cells Market, Global Research Reports 2020-2021
This report covers market size and forecasts of Induced Pluripotent Stem Cells, including the following market information:
Major competitors identified in this market include Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis, etc.
Based on the Region:
- Global Induced Pluripotent Stem Cells Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Induced Pluripotent Stem Cells Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Induced Pluripotent Stem Cells Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
- Global Induced Pluripotent Stem Cells Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Major competitors identified in this market include Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis, etc.
Based on the Region:
- Asia-Pacific (China, Japan, South Korea, India and ASEAN)
- North America (US and Canada)
- Europe (Germany, France, UK and Italy)
- Rest of World (Latin America, Middle East & Africa)
- Hepatocytes
- Fibroblasts
- Keratinocytes
- Amniotic Cells
- Others
- Academic Research
- Drug Development And Discovery
- Toxicity Screening
- Regenerative Medicine
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Induced Pluripotent Stem Cells Industry
1.7 COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends
2 GLOBAL INDUCED PLURIPOTENT STEM CELLS QUARTERLY MARKET SIZE ANALYSIS
2.1 Induced Pluripotent Stem Cells Business Impact Assessment - COVID-19
2.1.1 Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Induced Pluripotent Stem Cells Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Induced Pluripotent Stem Cells Quarterly Market Size, 2019 VS 2020
3.2 By Players, Induced Pluripotent Stem Cells Headquarters and Area Served
3.3 Date of Key Players Enter into Induced Pluripotent Stem Cells Market
3.4 Key Players Induced Pluripotent Stem Cells Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON INDUCED PLURIPOTENT STEM CELLS SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Hepatocytes
1.4.2 Fibroblasts
1.4.3 Keratinocytes
1.4.4 Amniotic Cells
1.4.5 Others
4.2 By Type, Global Induced Pluripotent Stem Cells Market Size, 2019-2021
5 IMPACT OF COVID-19 ON INDUCED PLURIPOTENT STEM CELLS SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Academic Research
5.5.2 Drug Development And Discovery
5.5.3 Toxicity Screening
5.5.4 Regenerative Medicine
5.2 By Application, Global Induced Pluripotent Stem Cells Market Size, 2019-2021
5.2.1 By Application, Global Induced Pluripotent Stem Cells Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Fujifilm Holding Corporation
7.1.1 Fujifilm Holding Corporation Business Overview
7.1.2 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.1.3 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product Introduction
7.1.4 Fujifilm Holding Corporation Response to COVID-19 and Related Developments
7.2 Astellas Pharma
7.2.1 Astellas Pharma Business Overview
7.2.2 Astellas Pharma Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.2.3 Astellas Pharma Induced Pluripotent Stem Cells Product Introduction
7.2.4 Astellas Pharma Response to COVID-19 and Related Developments
7.3 Fate Therapeutics
7.3.1 Fate Therapeutics Business Overview
7.3.2 Fate Therapeutics Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.3.3 Fate Therapeutics Induced Pluripotent Stem Cells Product Introduction
7.3.4 Fate Therapeutics Response to COVID-19 and Related Developments
7.4 Bristol-Myers Squibb Company
7.4.1 Bristol-Myers Squibb Company Business Overview
7.4.2 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.4.3 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product Introduction
7.4.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
7.5 ViaCyte
7.5.1 ViaCyte Business Overview
7.5.2 ViaCyte Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.5.3 ViaCyte Induced Pluripotent Stem Cells Product Introduction
7.5.4 ViaCyte Response to COVID-19 and Related Developments
7.6 Celgene Corporation
7.6.1 Celgene Corporation Business Overview
7.6.2 Celgene Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.6.3 Celgene Corporation Induced Pluripotent Stem Cells Product Introduction
7.6.4 Celgene Corporation Response to COVID-19 and Related Developments
7.7 Aastrom Biosciences
7.7.1 Aastrom Biosciences Business Overview
7.7.2 Aastrom Biosciences Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.7.3 Aastrom Biosciences Induced Pluripotent Stem Cells Product Introduction
7.7.4 Aastrom Biosciences Response to COVID-19 and Related Developments
7.8 Acelity Holdings
7.8.1 Acelity Holdings Business Overview
7.8.2 Acelity Holdings Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.8.3 Acelity Holdings Induced Pluripotent Stem Cells Product Introduction
7.8.4 Acelity Holdings Response to COVID-19 and Related Developments
7.9 StemCells
7.9.1 StemCells Business Overview
7.9.2 StemCells Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.9.3 StemCells Induced Pluripotent Stem Cells Product Introduction
7.9.4 StemCells Response to COVID-19 and Related Developments
7.10 Japan Tissue Engineering
7.10.1 Japan Tissue Engineering Business Overview
7.10.2 Japan Tissue Engineering Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.10.3 Japan Tissue Engineering Induced Pluripotent Stem Cells Product Introduction
7.10.4 Japan Tissue Engineering Response to COVID-19 and Related Developments
7.11 Organogenesis
7.11.1 Organogenesis Business Overview
7.11.2 Organogenesis Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.11.3 Organogenesis Induced Pluripotent Stem Cells Product Introduction
7.11.4 Organogenesis Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Induced Pluripotent Stem Cells Industry
1.7 COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends
2 GLOBAL INDUCED PLURIPOTENT STEM CELLS QUARTERLY MARKET SIZE ANALYSIS
2.1 Induced Pluripotent Stem Cells Business Impact Assessment - COVID-19
2.1.1 Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Induced Pluripotent Stem Cells Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 QUARTERLY COMPETITIVE ASSESSMENT, 2020
3.1 By Players, Global Induced Pluripotent Stem Cells Quarterly Market Size, 2019 VS 2020
3.2 By Players, Induced Pluripotent Stem Cells Headquarters and Area Served
3.3 Date of Key Players Enter into Induced Pluripotent Stem Cells Market
3.4 Key Players Induced Pluripotent Stem Cells Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 IMPACT OF COVID-19 ON INDUCED PLURIPOTENT STEM CELLS SEGMENTS, BY TYPE
4.1 Introduction
1.4.1 Hepatocytes
1.4.2 Fibroblasts
1.4.3 Keratinocytes
1.4.4 Amniotic Cells
1.4.5 Others
4.2 By Type, Global Induced Pluripotent Stem Cells Market Size, 2019-2021
5 IMPACT OF COVID-19 ON INDUCED PLURIPOTENT STEM CELLS SEGMENTS, BY APPLICATION
5.1 Overview
5.5.1 Academic Research
5.5.2 Drug Development And Discovery
5.5.3 Toxicity Screening
5.5.4 Regenerative Medicine
5.2 By Application, Global Induced Pluripotent Stem Cells Market Size, 2019-2021
5.2.1 By Application, Global Induced Pluripotent Stem Cells Market Size by Application, 2019-2021
6 GEOGRAPHIC ANALYSIS
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 COMPANY PROFILES
7.1 Fujifilm Holding Corporation
7.1.1 Fujifilm Holding Corporation Business Overview
7.1.2 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.1.3 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product Introduction
7.1.4 Fujifilm Holding Corporation Response to COVID-19 and Related Developments
7.2 Astellas Pharma
7.2.1 Astellas Pharma Business Overview
7.2.2 Astellas Pharma Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.2.3 Astellas Pharma Induced Pluripotent Stem Cells Product Introduction
7.2.4 Astellas Pharma Response to COVID-19 and Related Developments
7.3 Fate Therapeutics
7.3.1 Fate Therapeutics Business Overview
7.3.2 Fate Therapeutics Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.3.3 Fate Therapeutics Induced Pluripotent Stem Cells Product Introduction
7.3.4 Fate Therapeutics Response to COVID-19 and Related Developments
7.4 Bristol-Myers Squibb Company
7.4.1 Bristol-Myers Squibb Company Business Overview
7.4.2 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.4.3 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product Introduction
7.4.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
7.5 ViaCyte
7.5.1 ViaCyte Business Overview
7.5.2 ViaCyte Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.5.3 ViaCyte Induced Pluripotent Stem Cells Product Introduction
7.5.4 ViaCyte Response to COVID-19 and Related Developments
7.6 Celgene Corporation
7.6.1 Celgene Corporation Business Overview
7.6.2 Celgene Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.6.3 Celgene Corporation Induced Pluripotent Stem Cells Product Introduction
7.6.4 Celgene Corporation Response to COVID-19 and Related Developments
7.7 Aastrom Biosciences
7.7.1 Aastrom Biosciences Business Overview
7.7.2 Aastrom Biosciences Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.7.3 Aastrom Biosciences Induced Pluripotent Stem Cells Product Introduction
7.7.4 Aastrom Biosciences Response to COVID-19 and Related Developments
7.8 Acelity Holdings
7.8.1 Acelity Holdings Business Overview
7.8.2 Acelity Holdings Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.8.3 Acelity Holdings Induced Pluripotent Stem Cells Product Introduction
7.8.4 Acelity Holdings Response to COVID-19 and Related Developments
7.9 StemCells
7.9.1 StemCells Business Overview
7.9.2 StemCells Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.9.3 StemCells Induced Pluripotent Stem Cells Product Introduction
7.9.4 StemCells Response to COVID-19 and Related Developments
7.10 Japan Tissue Engineering
7.10.1 Japan Tissue Engineering Business Overview
7.10.2 Japan Tissue Engineering Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.10.3 Japan Tissue Engineering Induced Pluripotent Stem Cells Product Introduction
7.10.4 Japan Tissue Engineering Response to COVID-19 and Related Developments
7.11 Organogenesis
7.11.1 Organogenesis Business Overview
7.11.2 Organogenesis Induced Pluripotent Stem Cells Quarterly Revenue, 2020
7.11.3 Organogenesis Induced Pluripotent Stem Cells Product Introduction
7.11.4 Organogenesis Response to COVID-19 and Related Developments
8 KEY FINDINGS
9 APPENDIX
9.1 About US
9.2 Disclaimer
LIST OF TABLES
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Induced Pluripotent Stem Cells Assessment
Table 9. COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends
Table 10. COVID-19 Impact Global Induced Pluripotent Stem Cells Market Size
Table 11. Global Induced Pluripotent Stem Cells Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Induced Pluripotent Stem Cells Market Growth Drivers
Table 14. Global Induced Pluripotent Stem Cells Market Restraints
Table 15. Global Induced Pluripotent Stem Cells Market Opportunities
Table 16. Global Induced Pluripotent Stem Cells Market Challenges
Table 17. By Players, Induced Pluripotent Stem Cells Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Induced Pluripotent Stem Cells Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Induced Pluripotent Stem Cells Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Induced Pluripotent Stem Cells Market
Table 21. Key Players Induced Pluripotent Stem Cells Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Induced Pluripotent Stem Cells Market Size 2019-2021, (US$ Million)
Table 24. Global Induced Pluripotent Stem Cells Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Induced Pluripotent Stem Cells Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 57. Fujifilm Holding Corporation Business Overview
Table 58. Fujifilm Holding Corporation Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product
Table 60. Fujifilm Holding Corporation Response to COVID-19 and Related Developments
Table 61. Astellas Pharma Business Overview
Table 62. Astellas Pharma Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Astellas Pharma Induced Pluripotent Stem Cells Product
Table 64. Astellas Pharma Response to COVID-19 and Related Developments
Table 65. Fate Therapeutics Business Overview
Table 66. Fate Therapeutics Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Fate Therapeutics Induced Pluripotent Stem Cells Product
Table 68. Fate Therapeutics Response to COVID-19 and Related Developments
Table 69. Bristol-Myers Squibb Company Business Overview
Table 70. Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product
Table 72. Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
Table 73. ViaCyte Business Overview
Table 74. ViaCyte Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. ViaCyte Induced Pluripotent Stem Cells Product
Table 76. ViaCyte Response to COVID-19 and Related Developments
Table 77. Celgene Corporation Business Overview
Table 78. Celgene Corporation Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Celgene Corporation Induced Pluripotent Stem Cells Product
Table 80. Celgene Corporation Response to COVID-19 and Related Developments
Table 81. Aastrom Biosciences Business Overview
Table 82. Aastrom Biosciences Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Aastrom Biosciences Induced Pluripotent Stem Cells Product
Table 84. Aastrom Biosciences Response to COVID-19 and Related Developments
Table 85. Acelity Holdings Business Overview
Table 86. Acelity Holdings Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Acelity Holdings Induced Pluripotent Stem Cells Product
Table 88. Acelity Holdings Response to COVID-19 and Related Developments
Table 89. StemCells Business Overview
Table 90. StemCells Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. StemCells Induced Pluripotent Stem Cells Product
Table 92. StemCells Response to COVID-19 and Related Developments
Table 93. Japan Tissue Engineering Business Overview
Table 94. Japan Tissue Engineering Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Japan Tissue Engineering Induced Pluripotent Stem Cells Product
Table 96. Japan Tissue Engineering Response to COVID-19 and Related Developments
Table 97. Organogenesis Business Overview
Table 98. Organogenesis Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Organogenesis Induced Pluripotent Stem Cells Product
Table 100. Organogenesis Response to COVID-19 and Related Developments
Table 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Induced Pluripotent Stem Cells Assessment
Table 9. COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends
Table 10. COVID-19 Impact Global Induced Pluripotent Stem Cells Market Size
Table 11. Global Induced Pluripotent Stem Cells Quarterly Market Size, 2020 (US$ Million)
Table 12. Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 13. Global Induced Pluripotent Stem Cells Market Growth Drivers
Table 14. Global Induced Pluripotent Stem Cells Market Restraints
Table 15. Global Induced Pluripotent Stem Cells Market Opportunities
Table 16. Global Induced Pluripotent Stem Cells Market Challenges
Table 17. By Players, Induced Pluripotent Stem Cells Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 18. Key Players, Induced Pluripotent Stem Cells Revenue Market Share, 2019 VS 2020 (%)
Table 19. Key Induced Pluripotent Stem Cells Players Headquarters and Area Served
Table 20. Date of Key Players Enter into Induced Pluripotent Stem Cells Market
Table 21. Key Players Induced Pluripotent Stem Cells Product Type
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. By Players, Global Induced Pluripotent Stem Cells Market Size 2019-2021, (US$ Million)
Table 24. Global Induced Pluripotent Stem Cells Market Size by Application: 2019-2021 (US$ Million)
Table 25. Global Induced Pluripotent Stem Cells Market Size by Region, 2019-2021 (US$ Million)
Table 26. By Country, North America Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 27. By Type, US Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 28. By Application, US Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 29. By Type, Canada Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 30. By Application, Canada Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 32. By Country, Europe Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 33. By Type, Germany Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 34. By Application, Germany Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 35. By Type, France Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 36. By Application, France Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 37. By Type, UK Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 38. By Application, UK Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 39. By Type, Italy Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 40. By Application, Italy Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 42. By Region, Asia-Pacific Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 43. By Type, China Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 44. By Application, China Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 45. By Type, Japan Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 46. By Application, Japan Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 47. By Type, South Korea Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 48. By Application, South Korea Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 49. By Type, India Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 50. By Application, India Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 51. By Type, ASEAN Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 52. By Application, ASEAN Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 53. By Type, Latin America Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 54. By Application, Latin America Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 55. By Type, Middle East and Africa Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 56. By Application, Middle East and Africa Induced Pluripotent Stem Cells Market Size, 2019-2021 (US$ Million)
Table 57. Fujifilm Holding Corporation Business Overview
Table 58. Fujifilm Holding Corporation Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product
Table 60. Fujifilm Holding Corporation Response to COVID-19 and Related Developments
Table 61. Astellas Pharma Business Overview
Table 62. Astellas Pharma Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Astellas Pharma Induced Pluripotent Stem Cells Product
Table 64. Astellas Pharma Response to COVID-19 and Related Developments
Table 65. Fate Therapeutics Business Overview
Table 66. Fate Therapeutics Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Fate Therapeutics Induced Pluripotent Stem Cells Product
Table 68. Fate Therapeutics Response to COVID-19 and Related Developments
Table 69. Bristol-Myers Squibb Company Business Overview
Table 70. Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product
Table 72. Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
Table 73. ViaCyte Business Overview
Table 74. ViaCyte Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. ViaCyte Induced Pluripotent Stem Cells Product
Table 76. ViaCyte Response to COVID-19 and Related Developments
Table 77. Celgene Corporation Business Overview
Table 78. Celgene Corporation Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Celgene Corporation Induced Pluripotent Stem Cells Product
Table 80. Celgene Corporation Response to COVID-19 and Related Developments
Table 81. Aastrom Biosciences Business Overview
Table 82. Aastrom Biosciences Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. Aastrom Biosciences Induced Pluripotent Stem Cells Product
Table 84. Aastrom Biosciences Response to COVID-19 and Related Developments
Table 85. Acelity Holdings Business Overview
Table 86. Acelity Holdings Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Acelity Holdings Induced Pluripotent Stem Cells Product
Table 88. Acelity Holdings Response to COVID-19 and Related Developments
Table 89. StemCells Business Overview
Table 90. StemCells Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 91. StemCells Induced Pluripotent Stem Cells Product
Table 92. StemCells Response to COVID-19 and Related Developments
Table 93. Japan Tissue Engineering Business Overview
Table 94. Japan Tissue Engineering Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 95. Japan Tissue Engineering Induced Pluripotent Stem Cells Product
Table 96. Japan Tissue Engineering Response to COVID-19 and Related Developments
Table 97. Organogenesis Business Overview
Table 98. Organogenesis Induced Pluripotent Stem Cells Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020
Table 99. Organogenesis Induced Pluripotent Stem Cells Product
Table 100. Organogenesis Response to COVID-19 and Related Developments
LIST OF FIGURES
Figure 1. Induced Pluripotent Stem Cells Product Picture
Figure 2. Induced Pluripotent Stem Cells Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Induced Pluripotent Stem Cells Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Induced Pluripotent Stem Cells Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Induced Pluripotent Stem Cells Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Induced Pluripotent Stem Cells Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Induced Pluripotent Stem Cells Market Size Market Share, 2019-2021
Figure 1. Induced Pluripotent Stem Cells Product Picture
Figure 2. Induced Pluripotent Stem Cells Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Induced Pluripotent Stem Cells Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Induced Pluripotent Stem Cells Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Induced Pluripotent Stem Cells Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Induced Pluripotent Stem Cells Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Induced Pluripotent Stem Cells Market Size Market Share, 2019-2021
